title: A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein.
abstract: Untreated rabies virus (RABV) infection leads to death. Vaccine and postexposure treatment have been effective in preventing RABV infection. However, due to cost, rabies vaccination and treatment have not been widely used in developing countries. There are 55,000 human death caused by rabies annually. An efficacious and cost-effective rabies vaccine is needed. Parainfluenza virus 5 (PIV5) is thought to contribute to kennel cough, and kennel cough vaccines containing live PIV5 have been used in dogs for many years. In this work, a PIV5-vectored rabies vaccine was tested in mice. A recombinant PIV5 encoding RABV glycoprotein (G) (rPIV5-RV-G) was administered to mice via intranasal (i.n.), intramuscular (i.m.), and oral inoculation. The vaccinated mice were challenged with a 50% lethal challenge dose (LD(50)) of RABV challenge virus standard 24 (CVS-24) intracerebrally. A single dose of 10(6) PFU of rPIV5-RV-G was sufficient for 100% protection when administered via the i.n. route. The mice vaccinated with a single dose of 10(8) PFU of rPIV5-RV-G via the i.m. route showed very robust protection (90% to 100%). Intriguingly, the mice vaccinated orally with a single dose of 10(8) PFU of rPIV5-RV-G showed a 50% survival rate, which is comparable to the 60% survival rate among mice inoculated with an attenuated rabies vaccine strain, recombinant LBNSE. This is first report of an orally effective rabies vaccine candidate in animals based on PIV5 as a vector. These results indicate that rPIV5-RV-G is an excellent candidate for a new generation of recombinant rabies vaccine for humans and animals and PIV5 is a potential vector for oral vaccines.
authors.affiliation: Department of Infectious Disease, University of Georgia, Athens, GA, USA.
authors.forename: Zhenhai
authors.initials: Z
authors.lastname: Chen
authors.forename: Ming
authors.initials: M
authors.lastname: Zhou
authors.forename: Xiudan
authors.initials: X
authors.lastname: Gao
authors.forename: Guoqing
authors.initials: G
authors.lastname: Zhang
authors.forename: Guiping
authors.initials: G
authors.lastname: Ren
authors.forename: Clement W
authors.initials: CW
authors.lastname: Gnanadurai
authors.forename: Zhen F
authors.initials: ZF
authors.lastname: Fu
authors.forename: Biao
authors.initials: B
authors.lastname: He
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D000818:Animals; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D004195:Disease Models, Animal; D004337:Drug Carriers; D005822:Genetic Vectors; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology*; D007273:Injections, Intramuscular; D051379:Mice; D011818:Rabies / Q000276:immunology / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D018108:Respirovirus / Q000235:genetics*; D016019:Survival Analysis; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*
chemical_list: D000956:Antigens, Viral; D004337:Drug Carriers; D006023:Glycoproteins; D011819:Rabies Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C064951:glycoprotein G, Rabies virus